Premium
Multimodality therapy of stage III adenocarcinoma of the breast
Author(s) -
Bitran J. D.,
Desser R. K.,
Schifeling D.,
Shapiro C. M.,
Kozloff M. F.,
Robin E.,
Recant W.,
Michel A.,
Rochman H.,
Billings A. A.
Publication year - 1983
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930220103
Subject(s) - medicine , stage (stratigraphy) , radiation therapy , oncology , chemotherapy , adenocarcinoma , cancer , paleontology , biology
The results of a pilot multimodality program (surgery + radiotherapy + chemotherapy) are reported in 34 women with advanced stage III and IV adenocarcinoma of the breast. The median relapse‐free survival for all patients was 24 months, with 74% of the premenopausal patients and 37% of the postmenopausal alive at five years (P = 0.18). The relapse rate was significantly lower in premenopausal patients when compared to the postmenopausal subgroup. Estrogen receptor status was not predictive for relapse or survival.